Hyman Charles D Invests $222,000 in CVS Health Co. (NYSE:CVS)

Hyman Charles D purchased a new stake in CVS Health Co. (NYSE:CVS) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,818 shares of the pharmacy operator’s stock, valued at approximately $222,000.

Other institutional investors have also recently bought and sold shares of the company. Gryphon Financial Partners LLC boosted its holdings in shares of CVS Health by 48.3% in the fourth quarter. Gryphon Financial Partners LLC now owns 8,151 shares of the pharmacy operator’s stock worth $654,000 after buying an additional 2,653 shares during the period. Pacific Capital Wealth Advisors Inc. acquired a new position in shares of CVS Health in the fourth quarter worth about $135,000. Patrick M Sweeney & Associates Inc. purchased a new stake in shares of CVS Health in the fourth quarter worth approximately $5,370,000. Palisade Asset Management LLC lifted its position in shares of CVS Health by 9.7% in the fourth quarter. Palisade Asset Management LLC now owns 7,118 shares of the pharmacy operator’s stock worth $562,000 after purchasing an additional 630 shares in the last quarter. Finally, Peddock Capital Advisors LLC lifted its position in shares of CVS Health by 3.4% in the fourth quarter. Peddock Capital Advisors LLC now owns 22,506 shares of the pharmacy operator’s stock worth $1,777,000 after purchasing an additional 735 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of CVS Health stock traded down $0.23 during midday trading on Tuesday, hitting $55.74. The company had a trading volume of 17,144,275 shares, compared to its average volume of 11,872,880. The business’s 50 day simple moving average is $71.95 and its two-hundred day simple moving average is $73.09. The stock has a market cap of $69.97 billion, a PE ratio of 9.80, a P/E/G ratio of 0.88 and a beta of 0.56. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.81 and a quick ratio of 0.61. CVS Health Co. has a 1-year low of $53.70 and a 1-year high of $83.25.

CVS Health (NYSE:CVS) last announced its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.69 by ($0.38). The company had revenue of $88.44 billion during the quarter, compared to analyst estimates of $89.33 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The company’s revenue was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.20 EPS. As a group, equities analysts predict that CVS Health Co. will post 7.03 EPS for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a yield of 4.77%. CVS Health’s dividend payout ratio is currently 46.75%.

Insiders Place Their Bets

In other CVS Health news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction on Friday, February 16th. The shares were sold at an average price of $76.95, for a total transaction of $2,267,947.35. Following the sale, the executive vice president now owns 39,765 shares in the company, valued at $3,059,916.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Edward J. Ludwig acquired 1,000 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was bought at an average cost of $53.88 per share, with a total value of $53,880.00. Following the completion of the acquisition, the director now owns 21,630 shares in the company, valued at $1,165,424.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction on Friday, February 16th. The shares were sold at an average price of $76.95, for a total value of $2,267,947.35. Following the transaction, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at $3,059,916.75. The disclosure for this sale can be found here. Corporate insiders own 0.24% of the company’s stock.

Analyst Upgrades and Downgrades

CVS has been the subject of a number of research analyst reports. TD Cowen lowered shares of CVS Health from a “buy” rating to a “hold” rating and reduced their price target for the stock from $99.00 to $59.00 in a research report on Tuesday. UBS Group lowered shares of CVS Health from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $85.00 to $60.00 in a research report on Thursday, May 2nd. Bank of America reduced their price target on shares of CVS Health from $95.00 to $77.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Royal Bank of Canada cut their price objective on shares of CVS Health from $86.00 to $84.00 and set an “outperform” rating on the stock in a research report on Thursday, February 8th. Finally, StockNews.com lowered shares of CVS Health from a “buy” rating to a “hold” rating in a research report on Thursday, February 15th. Nine investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.55.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.